Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 64 Significant growth in GLP-1 market with leading market share for VictozaⓇ Global GLP-1 market value and share of total diabetes care market value exenatide Novo Nordisk GLP-1 value market share leading in all regions except Japan & Korea ☐ Novo Nordisk GLP-1 value market share VictozaⓇ DKK billion albiglutide1 70 60 50 exenatide launch 40 30 20 10 2005 dulaglutide lixisenatide GLP-1 share of total diabetes care market DKK billion FDA/EMA statement on 14% 60 47% pancreatic safety³ 12% 50 Dulaglutide Article on launch 10% pancreatic safety 40 of incretins² - 8% 30 VICTOZA - 6% liraglutide injection 20 - 4% - 2% 10 57% 38% 73% 47% 72% 0% 0 2009 2013 2014 2018 North America Region Region Region Region Europe J&K LATAM AAMEO Region China 1 Manufacturing and sale of albiglutide to be discontinued by Jul 2018 2 Butler et al, Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors, Diabetes, Vol. 62, Jul 2013' 3 Egan et al, Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment, The New England Journal of Medicine 370;9, 27 Feb 2014 Source: IQVIA MIDAS, monthly data, Feb 2018 (Note: IQVIA data does not adequately capture rebates resulting in an overstatement of market value) FDA: US Food and Drug Administration; EMA: European Medicines Agency AAMEO: Africa, Asia, Middle-East and Oceania; J&K: Japan & Korea; LATAM: Latin America Source: Reported sales until Feb 2018; IQVIA MIDAS, Feb 2018 novo nordisk

View entire presentation